Synthetic pathways of gallbladder mucosal prostanoids: The role of cyclooxygenase-1 and 2

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 60, Issue 2, 1999, Pages 77-85

  Longo, W E ^a   Panesar, N ^a   Mazuski, J E ^a   Kaminski, D ^a  

^a Department of Surgery   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 OXOPROSTAGLANDIN F1 ALPHA; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; LIPOPOLYSACCHARIDE; LYSOPHOSPHATIDYLCHOLINE; PROSTAGLANDIN E2; PROSTANOID;

ADULT; ARTICLE; CELL CULTURE; CELL TRANSFORMATION; CHOLECYSTECTOMY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GALLBLADDER CANCER; GALLBLADDER MUCOSA; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; WESTERN BLOTTING;

EID: 0033081731     PISSN: 09523278     EISSN: None     Source Type: Journal    
DOI: 10.1054/plef.1999.0011     Document Type: Article

References (50)

1. Thornell E., Kral J. G., Jansson R., Svanvik J. Inhibition of prostaglandin synthesis as a treatment for biliary pain. Lancet 1979; 1: 584.
2. Thronell E., Jansson R., Svanvik J. Indomethacin intravenously - A new way for effective relief of biliary pain: A double blind study in man. Surgery 1981; 90: 468-472.
3. Kaminski D. L., Deshpande Y. G., Thomas L., Qualy J., Blank W. The effect of oral ibuprofen on the formation of prostaglandin E and F by human gallbladder muscle and mucosa. Dig Dis Sci 1985; 30: 933-940.
4. Goldman G., Kahn P. J., Alon R., Witznitzer T. Biliary colic treatment and acute cholecystitis prevention by prostaglandin inhibitor. Dig Dis Sci 1989; 34: 809-811.
5. Lundstam S., Ivarsson L., Lindblad L., Kral J. G. Treatment of biliary pain by prostaglandin synthetase inhibition with diclofenac sodium. Curr Ther Res 1985; 37: 435-439.
6. Karachalios G. N., Tsimiklis S., Asimakis G., Helas G. Treatment of biliary colic with prostaglandin-synthetase inhibition: Diclofenac sodium. Singapore Med J 1986; 27: 207-209.
7. Akriviadis E. A., Hatzigavriel M., Kapnias D., Kirimlidis J., Markantas A., Garyfallos A. Treatment of biliary colic with diclofenac: A randomized, double-blind, placebo-controlled study. Gastroenterol 1997; 113: 225-231.
8. Babb R. B. Managing gallbladder disease with prostaglandin inhibitors. Postgrad Med 1993; 84: 127-130.
9. Lee S. P., Carey M. C., LaMont J. Aspirin prevention of cholesterol gallstone formation in prairie dogs. Science 1981; 211: 1429-1431.
10. Broomfield P. H., Chopra R., Scheinbaum R. C., et al. Effects of ursodeoxycholic acid and aspirin on the formation of lithogenic bile and gallstones during loss of weight. N Engl J Med 1988; 319: 1567-1572.
11. Xie W. L., Chipman J. G., Robertson D. L., Erikson R. L., Simmons D. L. Expression of a mitogen responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci USA 1991; 88: 2692-2696.
12. Miyamoto T. N., Ogino N., Yamamoto S., Hayaishi O. Purification of prostaglandin endoperoxide synthase from bovine vesicular gland microsomes. J Biol Chem 1976; 251: 2629-2636.
13. Seibert K., Masferrer J. L. Role of inducible cyclooxygenase (COX-2) in inflammation. Receptors 1994; 4: 17-23.
14. Simmons D. L., Levy D. B., Yannoni Y., Erikson R. L. Identification of a phorbol ester-repressible v-src, -inducible gene. Proc Natl Acad Sci USA 1989; 86: 1178-1182.
15. Williams C. S., DuBois R. N. Prostaglandin endoperoxide synthase: Why two isoforms? Am J Physiol 1996; 270 (Gastrointest Liver Physiol 33) G393-G400.
16. Kaminski D. L., Daneshmand H., Dean P., Deshpande Y. G. Prostaglandins and leukotrienes in experimental feline cholecystitis. Hepatol 1990; 11: 1003-1009.
17. Kaminski D. L., Feinstein W. K., Deshpande Y. G. The production of experimental cholecystitis by endotoxin. Prostaglandins 1994: 47: 233-245.
18. Kaminski D. L., Amir G., Deshpande Y. G., Beck D., Li A. P. Studies on the etiology of acute acalculous cholecystitis: The effect of lipopolysaccharide on human gallbladder mucosal cells. Prostaglandins 1994; 47: 319-330.
19. Nag M. K., Deshpande Y. G., Beck D., Li A. P., Kaminski D. L. The effect of lysolecithin on prostanoid and platelet-activating factor formation by human gallbladder mucosal cell. Med of Inflamm 1995; 4: 90-94.
20. Futaki N., Takahashi S., Yokoyama I., Higuchi S., Otomo S. NS-398, A new anti-inflammatory agent, Selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX-2) activity in vitro. Prostaglandins 1994; 47: 55-59.
21. Seibert K., Zhang Y., Leahy K., Hauser S., Masferrer J., Perkins W., Lee L., Isakson P. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc Natl Acad Sci USA 1994; 91: 12013-12017.
22. Bhattacharyya D. K., Lecomte M., Dunn J., Morgans D. J., Smith W. L. Selective inhibition of prostaglandin endoperoxide synthase-1 (cyclooxygenase-1) by valerylsalicyclic acid. Arch Biochem Biophys 1995; 317: 19-24.
23. Longo W. E., Damore L. J., Mazuski J. E., Smith G. S., Panesar N., Kaminski D. L. The role of cyclooxygenase-1 and cyclooxygenase-2 in lipopolysaccharide and interleukin-1 stimulated enterocyte prostanoid formation. Med Inflamm 1998; 7: 85-91.
24. Pistrilto G., Mancuso C., Tringali G., Perrelti M., Preziosi P., Navarra P. The relative contribution of constitutive and inducible cyclooxygenase activity to lipopolysaccharide-induced prostaglandin production by primary cultures of rat hypothalamic astrocytes. Neuroscience Letts 1998; 246: 45-48.
25. Longo W. E., Panesar N., Mazuski J., Kaminski D. L. Contribution of cyclooxygenase-1 and cyclooxygenase-2 to prostanoid formation by human enterocytes stimulated by inflammatory agents. Prostaglandins and Other Lipid Mediators 1998; 56: 325-339.
26. Donohue J. H., Nagorney D. M., Grant C. S., Isushima K., Ilstrup D. M., Adson M. A. Carcinoma of the gallbladder: Does radical resection improve survival? Arch Surg 1990; 125: 237-241.
27. Albores-Saavedra J,. Alcantra-Vazquez A., Cruz-Ortiz H., Herrera-Goepfert R. The precursor lesions of gallbladder carcinoma: Hyperplasia, atypical hyperplasia and carcinoma in-situ. Cancer 1980; 45: 919-927.
28. Shimada K., Yanagisawa J., Nakayama F. Increased lysophosphatidylcholine and pancreatic enzyme content in bile of patients with anomalous pancreaticobiliary ductal junction. Hepatology 1991; 13: 438-444.
29. Purdum P. P., Alessandra U., Hylemon P. B., Shiffman M. L., Moore E. W. Cultured human gallbladder epithelia. Lab Invest 1993; 68: 346-353.
30. Nag M. K., Deshpande Y. G., Li A. P., Beck D., Kaminski D. L. Lysophosphatidylcholine-stimulated protein and glycoprotein production by human gallbladder mucosal cells. Dig Dis Sci 1995; 40: 1990-1996.
31. Yoshitomi S., Miyazaki K., Makayama F. Demonstration and maintenance of mucous secretion in cultured human gallbladder epithelial cells. In Vitro Cell Dev Biol 1987; 28: 559-565.
32. Bradford M. M. A rapid and sensitive method for quantitation of microgram quantities of protein utilizing the principle of protein-dye-binding. Anal Biochem 1976; 72: 248-254.
33. Lee P.-P. H., Ip M. M. Regulation of proliferation of rat mammary tumor cells by inhibitors of cyclooxygenase and lipoxygenase. Prostaglandin Leukot Essent Fatty Acids 1992; 45: 21-31.
34. Kaminski D. L. Arachidonic acid metabolites in hepatobiliary physiology and disease. Gastroenterol 1989; 97: 781-792.
35. Masferrer J. L., Isakson P. C., Seibert K. Cyclooxygenase-2 inhibitors: A new class of anti-inflammatory agents that spare the gastrointestinal tract. Gastroenterol Clin North Am 1996; 25: 363-372.
36. Black H. E. Renal toxicity of nonsteroidal anti-inflammatory drugs. Toxicol Pathol 1986; 14: 83-90.
37. Johnson J. L., Maddipati K. R. Paradoxical effects of resveratrol on the two prostaglandin H synthetases. Pros and Other Lipid Med 1998; 56: 131-143.
38. Lupulescu A. Prostaglandins, their inhibitors and cancer. Prostaglandins Leukot Essent Fatty Acids 1996; 54: 83-94.
39. DuBois R. N., Smalley W. E. Cyclooxygenase, NSAIDs and colorectal cancer. J Gastroenterol 1996; 31: 898-906.
40. Neiderhiser D. H., Thornell E., Bjorck S., Svanvik J. The effect of lysophosphatidylcholine on gallbladder function in the cat. J Lab Clin Med 1983; 101: 699-707.
41. Neiderhiser D. H. Acute acalculous cholecystitis induced by lysophosphatidylcholine. Am J Pathol 1986; 124: 559-563.
42. Gottfries A., Nilsson S., Samuelsson B., Schersten T. Phospholipids in human bile and plasma in cases with acute cholecystitis. Scand J Lab Invest 1968; 21: 168-176.
43. Sjodahl R., Wetterfors J. Lysolecithin and lecithin in the gallbladder wall and bile: Their possible roles in the pathogenesis of acute cholecystitis. Scand J Gastroenterol 1974; 9: 519-525.
44. Sedlis S. P., Sequeira J. M., Ahumada G. G., El Sherif N. Effects of lysophosphatidylcholine on cultured heart cells: Correlation of rate of uptake and extent of cell injury. J Lab Clin Med 1988; 112: 745-754.
45. Lee S. P., Tasman-Jones C. Prevention of acute gastric ulceration in the rat by cimetidine, a histamine H2-receptor antagonist. Clin Exper Pharm Physiol 1978; 5: 61-••.
46. Schanne F. A. X., Kane A. B., Young E. E., Farber J. L. Calcium dependence of toxic cell death: A final common pathway. Science 1979; 206: 700-702.
47. Neiderhiser D. H., Morningstar W. A., Roth H. P. Absorption of lecithin and lysolecithin by the gallbladder. J Lab Clin Med 1973; 82: 891-897.
48. Homaidan F. R., Zhao L., Burakoff R. IL-1B induces synthesis of phospholipase A2 activating protein in rabbit distal colon. Am J Physiol 1997; 272 (Gastrointest Liver Physiol 35): 1338-1346.
49. Viriyakosol S., Kirkland T. Knowledge of cellular receptors for bacterial endotoxin-1995. Clin Inf Dis 1995; 21: suppl 2, s190-s195.
50. Smith G. S., Rieckenberg C., Longo W. E., Kaminski D. L., Mazuski J. E., Deshpande Y. G., Miller T. A. The effect of an interleukin receptor antagonist on colonocyte eicosanoid release. Med Inflamm 1996; 5: 449-452.